The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset

This is a generated summary. It shows the 9 most-liked posts from a topic of 65, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
VM
v.malinowskiTL26 Mar 2025#1

Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that.

Posting a small dataset on SURMOUNT-4 and continuation versus withdrawal. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately.

What I would like is not agreement but a second dataset collected by someone with no stake in mine. If one exists I would rather read it than argue for this one.

55 likes 17mo
LE
logbook_erinTL3Regular18 Apr 2025#18

Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.

25 likes 15mo
MY
m.yildizTL224 Apr 2025#21

The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.

I would not lead a decision with this, but I would not ignore it either.

25 likes 15mo
JM
j.marchettiTL22 May 2025#25

On SURMOUNT-4 and continuation versus withdrawal: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

18 likes 15mo
B
BGiordanoTL2Member14 May 2025#32

Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.

Reading it again, the caveat matters more than the finding.

23 likes 14mo
HM
h.mbekiTL221 May 2025#36

An hour is enough for one paper read properly and not enough for two read partly. The temptation is always to add the second.

Somebody will have a better source than mine, and I hope they post it.

31 likes 14mo
B
batchlogTL3Regular29 May 2025#41

Confirming post #39 from a second method, which matters more than confirming it from a second person.

Posting my SURMOUNT-4 and continuation versus withdrawal numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.

28 likes 14mo
SK
s.kuuselaTL221 Jun 2025#55

The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.

26 likes 13mo
AL
a.lindholmTL24 Jul 2025#64

What I can speak to on SURMOUNT-4 and continuation versus withdrawal is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

31 likes 13mo

Read the full topic (65 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…
FPHMLPAAVB+108 122 52k 7d
Journal club: indirect comparison between two programmes, defended and attacked — one year on
Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Asking about indirect…
BZNEMETLM+45 50 3k 9mo
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the…
MREPAKTWJD+18 22 2.5k 11mo
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…
AKACRIGKR+103 110 8.1k 2h
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
GKRCDALB+70 76 4.8k 15h

Related topics — sharing the tags randomised trial, risk of bias, effect size

TopicParticipantsRepliesViewsActivity
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…
MGJICLAIDO+75 81 2k 2y
Coming back to: Reading a meta-analysis you disagree with, fairly
Reading a meta-analysis you disagree with, fairly Writing it up because I had to work it out twice and would rather nobody else did. Reading a meta-analysis — I have the observation and I do not trust my…
TVBDJIPMCT+30 34 9.3k 17mo
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
MSFVJF 2 52k 1mo
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…
RIPREAGTMM+2 6 5.5k 7h
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about cagrilintide…
KDPOARNSJH 4 41k 12mo